The potential of heparanase as a therapeutic target in cancer

Biochemical Pharmacology

Volumn 89, Issue 1, 2014, Pages 12-19

  Pisano, Claudio ^a   Vlodavsky, Israel ^b   Ilan, Neta ^b   Zunino, Franco ^c  

^a Istituto di Ricerche Genetiche Gaetano Salvatore Biogem sc arl   (Italy)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antitumor therapy; Drug target; Heparanase; Heparanase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; ENZYME INHIBITOR; HEPARANASE; HEPARANASE INHIBITOR; HEPARIN; MONOCLONAL ANTIBODY; MUPARFOSTAT; NEUTRALIZING ANTIBODY; PG 545; PROTEOHEPARAN SULFATE; SST 0001; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CHRONIC INFLAMMATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; INFLAMMATION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

ANTITUMOR THERAPY; DRUG TARGET; HEPARANASE; HEPARANASE INHIBITORS;

DISEASE PROGRESSION; GLUCURONIDASE; HUMANS; INFLAMMATION; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84898001352     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.02.010     Document Type: Note

References (77)

1. L. Fux, N. Ilan, R.D. Sanderson, and I. Vlodavsky Heparanase: busy at the cell surface Trends Biochem Sci 34 2009 511 519
2. N. Gil, R. Goldberg, T. Neuman, M. Garsen, E. Zcharia, A. Rubinstein, and T. van Kuppevelt et al. Heparanase is essential for the development of diabetic nephropathy in mice Diabetes 61 2012 208 216
3. R.W. Li, C. Freeman, D. Yu, E.J. Hindmarsh, K.E. Tymms, and C.R. Parish et al. Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis Arthritis Rheum 58 2008 1590 1600 (Pubitemid 351847512)
4. C. Osterholm, L. Folkersen, M. Lengquist, F. Ponten, T. Renne, and J. Li et al. Increased expression of heparanase in symptomatic carotid atherosclerosis Atherosclerosis 226 2013 67 73
5. C.R. Parish, C. Freeman, A.F. Ziolkowski, Y.Q. He, E.L. Sutcliffe, and A. Zafar et al. Unexpected new roles for heparanase in Type 1 diabetes and immune gene regulation Matrix Biol 32 2013 228 233
6. V.C. Ramani, A. Purushothaman, M.D. Stewart, C.A. Thompson, I. Vlodavsky, and J.L. Au et al. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies FEBS J 280 2013 2294 2306
7. I. Vlodavsky, P. Beckhove, I. Lerner, C. Pisano, A. Meirovitz, and N. Ilan et al. Significance of heparanase in cancer and inflammation Cancer Microenviron 5 2012 115 132
8. I. Vlodavsky, M. Blich, J.P. Li, R.D. Sanderson, and N. Ilan Involvement of heparanase in atherosclerosis and other vessel wall pathologies Matrix Biol 32 2013 241 251
9. Y. Yang, Y. Ren, V.C. Ramani, L. Nan, L.J. Suva, and R.D. Sanderson Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL Cancer Res 70 2010 8329 8338
10. R. Goldberg, A. Meirovitz, N. Hirshoren, R. Bulvik, A. Binder, and A.M. Rubinstein et al. Versatile role of heparanase in inflammation Matrix Biol 32 2013 234 240
11. E. Hermano, I. Lerner, and M. Elkin Heparanase enzyme in chronic inflammatory bowel disease and colon cancer Cell Mol Life Sci 69 2012 2501 2513
12. J.P. Li, and I. Vlodavsky Heparin, heparan sulfate and heparanase in inflammatory reactions Thromb Haemost 102 2009 823 828
13. E.A. McKenzie Heparanase: a target for drug discovery in cancer and inflammation Br J Pharmacol 151 2007 1 14 (Pubitemid 46675998)
14. V. Vreys, and G. David Mammalian heparanase: what is the message J Cell Mol Med 11 2007 427 452
15. M. Bernfield, M. Gotte, P.W. Park, O. Reizes, M.L. Fitzgerald, and J. Lincecum et al. Functions of cell surface heparan sulfate proteoglycans Annu Rev Biochem 68 1999 729 777 (Pubitemid 29449208)
16. U. Hacker, K. Nybakken, and N. Perrimon Heparan sulphate proteoglycans: the sweet side of development Nature Rev 6 2005 530 541 (Pubitemid 40943044)
17. J.R. Couchman Transmembrane signaling proteoglycans Annu Rev Cell Dev Biol 26 2010 89 114
18. U. Lindahl, and J.P. Li Interactions between heparan sulfate and proteins-design and functional implications Int Rev Cell Mol Biol 276 2009 105 159
19. R.V. Iozzo, and R.D. Sanderson Proteoglycans in cancer biology, tumour microenvironment and angiogenesis J Cell Mol Med 15 2011 1013 1031
20. S.B. Peterson, and J. Liu Multi-faceted substrate specificity of heparanase Matrix Biol 32 2013 223 227
21. N. Ilan, M. Elkin, and I. Vlodavsky Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis Int J Biochem Cell Biol 38 2006 2018 2039 (Pubitemid 44397619)
22. M.D. Hulett, J.R. Hornby, S.J. Ohms, J. Zuegg, C. Freeman, and J.E. Gready et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase Biochemistry 39 2000 15659 15667 (Pubitemid 32038227)
23. G. Abboud-Jarrous, R. Atzmon, T. Peretz, C. Palermo, B.B. Gadea, and J.A. Joyce et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment J Biol Chem 283 2008 18167 18176
24. G. Cassinelli, C. Lanzi, M. Tortoreto, D. Cominetti, G. Petrangolini, and E. Favini et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models Biochem Pharmacol 85 2013 1424 1432
25. B. Casu, I. Vlodavsky, and R.D. Sanderson Non-anticoagulant heparins and inhibition of cancer Pathophysiol Haemost Thromb 36 2008 195 203
26. K. Dredge, E. Hammond, P. Handley, T.J. Gonda, M.T. Smith, and C. Vincent et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models Br J Cancer 104 2011 635 642
27. J.P. Ritchie, V.C. Ramani, Y. Ren, A. Naggi, G. Torri, and B. Casu et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis Clin Cancer Res 17 2011 1382 1393
28. I. Shafat, M.W. Ben-Arush, J. Issakov, I. Meller, I. Naroditsky, and M. Tortoreto et al. Pre-clinical and clinical significance of heparanase in Ewing's sarcoma J Cell Mol Med 15 2011 1857 1864
29. H. Zhou, S. Roy, E. Cochran, R. Zouaoui, C.L. Chu, and J. Duffner et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis PLoS ONE 6 2011 e21106
30. L. Bode, C. Salvestrini, P.W. Park, J.P. Li, J.D. Esko, and Y. Yamaguchi et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function J Clin Invest 118 2008 229 238
31. G.J. Brunn, M.K. Bungum, G.B. Johnson, and J.L. Platt Conditional signaling by Toll-like receptor 4 FASEB J 19 2005 872 874 (Pubitemid 40617413)
32. K.R. Taylor, and R.L. Gallo Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation FASEB J 20 2006 9 22 (Pubitemid 43100470)
33. L. Wang, M. Fuster, P. Sriramarao, and J.D. Esko Endothelial heparan sulfate deficiency impairs l-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses Nat Immunol 6 2005 902 910 (Pubitemid 43090445)
34. I. Vlodavsky, A. Eldor, A. Haimovitz-Friedman, Y. Matzner, R. Ishai-Michaeli, and O. Lider et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation Invasion Metastasis 12 1992 112 127
35. E. Edovitsky, I. Lerner, E. Zcharia, T. Peretz, I. Vlodavsky, and M. Elkin Role of endothelial heparanase in delayed-type hypersensitivity Blood 107 2006 3609 3616
36. I. Lerner, E. Hermano, E. Zcharia, D. Rodkin, R. Bulvik, and V. Doviner et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice J Clin Invest 121 2011 1709 1721
37. E.P. Schmidt, Y. Yang, W.J. Janssen, A. Gandjeva, M.J. Perez, and L. Barthel et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis Nat Med 18 2012 1217 1223
38. S. Massena, G. Christoffersson, E. Hjertstrom, E. Zcharia, I. Vlodavsky, and N. Ausmees et al. A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils Blood 116 2011 1924 1931
39. B. Wang, J. Jia, X. Zhang, E. Zcharia, I. Vlodavsky, and G. Pejler et al. Heparanase affects secretory granule homeostasis of murine mast cells through degrading heparin J Allergy Clin Immunol 128 2011 1310 1317 e8
40. X. Zhang, B. Wang, P. O'Callaghan, E. Hjertstrom, J. Jia, and F. Gong et al. Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-beta in murine brain Acta Neuropathol 124 2012 465 478
41. R.J. Xavier, and D.K. Podolsky Unravelling the pathogenesis of inflammatory bowel disease Nature 448 2007 427 434 (Pubitemid 47123518)
42. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer-related inflammation Nature 454 2008 436 444
43. S.I. Grivennikov, and M. Karin Inflammation and oncogenesis: a vicious connection Curr Opin Genet Dev 20 2010 65 71
44. B.Z. Qian, and J.W. Pollard Macrophage diversity enhances tumor progression and metastasis Cell 141 2010 39 51
45. R. Brun, I. Naroditsky, M. Waterman, O. Ben-Izhak, G. Groisman, and N. Ilan et al. Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression Mod Pathol 22 2009 1548 1554
46. O.N. El-Assal, A. Yamanoi, T. Ono, H. Kohno, and N. Nagasue The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma Clin Cancer Res 7 2001 1299 1305 (Pubitemid 32708684)
47. A. Koliopanos, H. Friess, J. Kleeff, X. Shi, Q. Liao, and I. Pecker et al. Heparanase expression in primary and metastatic pancreatic cancer Cancer Res 61 2001 4655 4659 (Pubitemid 32691870)
48. N.S. Gandhi, C. Freeman, C.R. Parish, and R.L. Mancera Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-beta-d-glucuronidase (heparanase) Glycobiology 22 2012 35 55
49. R. Gozalbes, S. Mosulen, L. Orti, J. Rodriguez-Diaz, R.J. Carbajo, and P. Melnyk et al. Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches Bioorg Med Chem 21 2013 1944 1951
50. N. Sapay, E. Cabannes, M. Petitou, and A. Imberty Molecular model of human heparanase with proposed binding mode of a heparan sulfate oligosaccharide and catalytic amino acids Biopolymers 97 2012 21 34
51. A. Naggi, B. Casu, M. Perez, G. Torri, G. Cassinelli, and S. Penco et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting J Biol Chem 280 2005 12103 12113
52. A. Meirovitz, E. Hermano, I. Lerner, E. Zcharia, C. Pisano, and T. Peretz et al. Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma Cancer Res 71 2011 2772 2780
53. V. Ferro, K. Dredge, L. Liu, E. Hammond, I. Bytheway, and C. Li et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis Semin Thromb Hemost 33 2007 557 568
54. C.J. Liu, P.H. Lee, D.Y. Lin, C.C. Wu, L.B. Jeng, and P.W. Lin et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage J Hepatol 50 2009 958 968
55. L. Borsig, I. Vlodavsky, R. Ishai-Michaeli, G. Torri, and E. Vismara Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase Neoplasia 13 2011 445 452
56. V. Ferro, L. Liu, K.D. Johnstone, N. Wimmer, T. Karoli, and P. Handley et al. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis J Med Chem 55 2012 3804 3813
57. K.D. Johnstone, T. Karoli, L. Liu, K. Dredge, E. Copeman, and C.P. Li et al. Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth J Med Chem 53 2010 1686 1699
58. E. Hammond, R. Brandt, and K. Dredge PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model PLOS ONE 7 2012 e52175
59. V. Ferro Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses Expert Opin Ther Targets 17 2013 965 975
60. J.R. Harvey, P. Mellor, H. Eldaly, T.W. Lennard, J.A. Kirby, and S. Ali Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids Clin Cancer Res 13 2007 1562 1570 (Pubitemid 46450448)
61. L. Ma, H. Qiao, C. He, Q. Yang, C.H. Cheung, and J.R. Kanwar et al. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer Invest New Drugs 30 2012 508 517
62. A. Palumbo, A. Larocca, M. Genuardi, K. Kotwica, F. Gay, and D. Rossi et al. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial Haematologica 95 2010 1144 1149
63. D.Y. Lee, K. Park, S.K. Kim, R.W. Park, I.C. Kwon, and S.Y. Kim et al. Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis Clin Cancer Res 14 2008 2841 2849
64. F. Robert The potential benefits of low-molecular-weight heparins in cancer patients J Hematol Oncol 3 2010 3
65. V. Ferro, E. Hammond, and J.K. Fairweather The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation Mini Rev Med Chem 4 2004 693 702 (Pubitemid 38961234)
66. A.L. Correia, and M.J. Bissell The tumor microenvironment is a dominant force in multidrug resistance Drug Resist Updat 15 2013 39 49
67. A. Ostman The tumor microenvironment controls drug sensitivity Nat Med 18 2013 1332 1334
68. O. Tredan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 2007 1441 1454
69. K.H. Paraiso, and K.S. Smalley Fibroblast-mediated drug resistance in cancer Biochem Pharmacol 85 2013 1033 1041
70. A.K. Azab, J.M. Runnels, C. Pitsillides, A.S. Moreau, F. Azab, and X. Leleu et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy Blood 113 2009 4341 4351
71. Y. Hu, M. Gale, J. Shields, C. Garron, M. Swistak, and T.H. Nguyen et al. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists Leukemia Lymphoma 53 2012 130 138
72. E. Hanna, J. Quick, and S.K. Libutti The tumour microenvironment: a novel target for cancer therapy Oral Dis 15 2009 8 17
73. V.C. Ramani, Y. Yang, Y. Ren, L. Nan, and R.D. Sanderson Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity J Biol Chem 286 2011 6490 6499
74. T.L. Underiner, T. Herbertz, and S.J. Miknyoczki Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates Anti-cancer Agents Med Chem 10 2010 7 27
75. H.L. Goel, and A.M. Mercurio VEGF targets the tumour cell Nature Rev 13 2013 871 882
76. S. Dalal, A.M. Berry, C.J. Cullinane, D.C. Mangham, R. Grimer, and I.J. Lewis et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family Clin Cancer Res 11 2005 2364 2378 (Pubitemid 40490198)
77. G. Cassinelli, V. Zuco, G. Petrangolini, M. De Cesare, M. Tortoreto, and C. Lanzi et al. The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects Biochem Pharmacol 84 2012 163 171